Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolatav Study: Dolutegravir + Atazanavir/r in HIV-1 virologic failure
2015-001206-33Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dolutegravir, atazanavir and ritonavir in human immunodeficiency virus infection (HIV), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Virologic suppression at week 24. Started May 2021; status: completed.
02
Drugs
dolutegraviratazanavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2015-001206-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001206-33.